The Effects of Breakfast Size on Hormonal Profile in Adults With Type 2 Diabetes Mellitus

NCT ID: NCT01178723

Last Updated: 2010-08-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Studies has found a connection between breakfast consumption and obesity and obesity-related complications, but only few studies examined the effect of breakfast size.

The purpose of this study is to examine the effect of breakfast size on several parameters in adults with Type 2 diabetes mellitus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The prevalence of obesity has rapidly increased during recent decades, while the prevalence of skipping breakfast has increased.

Several studies have reported inverse relationships between the consumption of breakfast and BMI and weight gain. A study that examined the effect of breakfast size, found that an increased percentage of daily energy consumed at breakfast was associated with relatively lower weight gain. Preliminary results of clinical research (unpublished) show a connection between a large breakfast and weight loss and increased feeling of satiety throughout the day.

The purpose of this study is to examine the effect of breakfast size on blood glucose balance, and its correlation with hormonal profile (including appetite hormones), adipokines and pro-inflammatory cytokines, weight and body composition and lipid profile in adults with type 2 diabetes.

The study will use a randomized-controlled, non-blinded, prospective design, including 48 participants with type 2 diabetes, who are not insulin dependent.

The research group will receive instructions to eat a large breakfast compared with the control group that will receive instructions to eat a small breakfast.

The estimated duration of the study is about three months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

breakfast size

The research group will receive instructions to eat a large breakfast, Dividing the total daily calories recommended to the patient to: breakfast - 1/8 of the total daily calories , lunch - 1/3 of the total daily calories and supper- 1/3 of the total daily calories.

(the rest of the calories will be snacks between the meals) In contrast, the control group that will receive instructions to eat a small breakfast.

Dividing the total daily calories recommended to the patient to: breakfast - 1/3 of the total daily calories , lunch - 1/4 of the total daily calories and supper- 1/4 of the total daily calories (the rest of the calories will snacks between the meals).

The instructions will be adapted to each patient individually

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women ages: 30-70
* Type 2 diabetics who are treated on a diet and / or pills
* Patients who receive a stable drug treatment (no change in the type/dosage of drugs during the three months preceding the research)
* Obese or overweight (35\> BMI\> 25)
* Patients who did not participate in another research for at least 30 days
* Patients who agree to sign a consent form and participate in research
* Patients with high compliance.

Exclusion Criteria

* Patients under the age 30 or over 70
* Type 1 I diabetics
* Patients who are insulin dependent
* Type 2 diabetics who are treated with injections
* BMI less than 25 or BMI over 35
* Patients who had Bariatric surgery
* Patients with food absorption disorders
* Active malignant disease
* Thyroid function disorder
* Active psychiatric illness
* Pregnancy / breastfeeding
Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wolfson Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wolfson Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Diabetes Unit, Wolfson Medical Center

Holon, , Israel

Site Status

Diabetes Unit, Wolfson Medical Center

Holon, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Julio Wainstein, M.D

Role: CONTACT

03-5028716

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Julio Wainstein, M.D

Role: primary

03-5028716

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TASMC10JW0080CTIL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Postprandial Dysmetabolism
NCT00813215 UNKNOWN NA